

Mailed: July 30, 2004

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Jose L. Boyer, et. al.

Art Unit:

Not yet Assigned

Appl. No.: 10/814,007 Examiner: Not yet Assigned

Filed: March 30, 2004

Atty. Docket: 03678.0064.CPUS02

COMPOSITION AND METHOD

Confirmation No.: Not yet Assigned

FOR INHIBITING PLATELET

AGGREGATION

Supplemental Information Disclosure Statement

MS Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Listed on accompanying Form PTO-1449 are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98.

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicants have listed publication dates on the attached PTO-1449 based on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist. The Examiner is specifically requested not to rely solely on the material submitted herewith. It is further understood that the Examiner will consider information that had been cited by or submitted to the U.S. Patent and Trademark Office in a prior application relied on under 35 U.S.C. § 120. 1138 OG 37, 38 (May 19, 1992).

Applicants have checked the appropriate boxes below.

- □ 1. This Information Disclosure Statement is being filed;
 - □ a. Within three months of the U.S. filing date of a national application other than a continued prosecution application under §1.53(d);
 - □ b. Within three months of the date of entry of the national stage as set forth in §1.491 in an international application;
 - c. Before the mailing date of a first Office Action on the merits;
 - □ d. Before the mailing of a first Office Action after filing of a request for continued examination under § 1.115.

No statement under 37 C.F.R. § 1.97(e) or fee is required.

or;

- □ 2. This Information Disclosure Statement is being filed after the period specified in paragraph 1(a)-1(d) above, but before the mailing date of a Final Rejection or Notice of Allowance, or action that otherwise closes prosecution in the application, and
 - □ a. I hereby state that each item of information contained in this Information

 Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement. 37

 C.F.R. § 1.97(e)(1), or
 - □ b. I hereby state that no item of information in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to my knowledge after making reasonable inquiry, no item of information contained in this Information Disclosure

- 3 -

Statement was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. § 1.97(e)(2), or

- Attached is our Check No. ____ in the amount of \$ ____ in payment of the fee □ c. under 37 C.F.R. § 1.17(p).
- **3**. This Information Disclosure Statement is being filed more than three months after the U.S. filing date and after the mailing date of a Final Rejection or Notice of Allowance, but on or before payment of the Issue Fee. Attached is our Check No. in the amount of \$ ____ in payment of the fee under 37 C.F.R. § 1.17(i), and
 - □ a. I hereby state that each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. $\S 1.97(e)(1)$, or
 - □ b. I hereby state that no item of information in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to my knowledge after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. § 1.97(e)(2).
- Relevance of the non-English language document(s) is discussed in the present **4**. specification.
- **□** 5. The document(s) was/were cited in a corresponding foreign application. An English language version of the foreign search report is attached for the Examiner's information.
- **□** 6. A concise explanation of the relevance of the non-English language document(s) appears below:

Application No.: 10/814,007 Docket No. 03678.0064.CPUS02

- 4 -

□ 7.	The	Examiner's	attention	is	directed	to	co-pending	U.S.	Patent	Application	No.
		·	, filed		, wh	ich	is directed to	relate	d techni	cal subject ma	atter.
		The iden	tification	of t	his U.S.	Pate	ent Applicati	on is	not to 1	oe construed	as a
	•	waiver of secrecy as to that application now or upon issuance of the prese							esent		
	application as a patent. The Examiner is respectfully requested to consider							r the			
		cited appl	ication and	i the	e art cited	the	rein during ex	kamina	ation.		

■ 8. Copies of all the documents, listed in 1449 Form were cited by or submitted to the Office in Application No. 09/643,138, filed August 21, 2000, which is relied upon for an earlier filing date under 35 U.S.C. § 120. Thus, copies of these documents are not attached. 37 C.F.R. § 1.98(d).

It is respectfully requested that the Examiner initial and return a copy of the enclosed PTO-1449, and to indicate in the official file wrapper of this patent application that the documents have been considered.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 08-3038 referencing docket number 03678.0064.CPUS02.

Respectfully submitted,

Date: July 30, 2004

Viola T. Kung (Reg. No. 41,131)

Unol If

HOWREY SIMON ARNOLD & WHITE, LLP 2941 Fairview Park Drive, Box 7 Falls Church, VA 22042

Telephone: (650) 463-8181 Facsimile: (650) 463-8400



LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

PTO FORM 1449

ATTORNEY DOCKET NO. 03678.0064.CPUS02	APPLICATION NO. 10/814,007					
APPLICANT						
BOYER, et al.						
FILING DATE	GROUP					
March 30, 2004	Not yet					

*EXAMINER		DOCUMENT NUMBER	DATE	NAME	CLASS	st	SUBCLASS		FILING DATE	
		US 4,621,076	11/04/86							
			FOREIGN PA	TENT DOCUMENTS			·			
*EXAMINER		DOCUMENT NUMBER	DATE	COUNTRY		CLASS	SUBCLASS	TRANSL		
	1.	WO 99/61012	12/02/99	PCT				YES	N	
	2.	WO 89/04321	05/18/89	РСТ					T	
	3.	GB 1407903	10/01/75	United Kingdom						
	4.	International Search Report PCT/US01/41818	03/11/02	РСТ						
		(Includin		REFERENCES , Date, Pertinent Pages,	Etc.)			_		
	5.	Hamilton, A. et al., "Design of Substrate-Site-Directed Inhibitors of Adenylate Kinase and Hexokinase. Effect of Substrate Substituents on Affinity for the Adenine Nucleotide Sites", J. Med. Chem., 19:1371-1377 (1976)								
	6.	Hiratsuka T., "Affinity Labeling of the Myosin ATPase with Ribose-Modified Fluorescent Nucleotides and Vanadate", <i>J. Biochem.</i> , <u>96</u> :147-154 (1984)								
	7.	Martin, P. et al., "Structure-Activity Studies of Analogs of β,γ-Methylene-ATP at P _{2x} -Purinoceptors in the Rabbit Ear Central Artery", <i>Drug Development Research</i> , <u>36</u> : 153-165 (1995) Metzker, M. et al., "Termination of DNA synthesis by novel3'-modified-deoxyribonucleoside 5'-triphophate", <i>Nucleic Acids Research</i> , <u>22</u> :4259-4267 (1994)						53-		
	8.									
		Pelicano, H. et al., "Study of the substrate-binding properties of bovine liver adenosine kinase and inhibition by fluorescent nucleoside analogues", Eur. J. Biochem., 248:930-937 (1997)								
	9.	kinase and inhibition 937 (1997)	by naorese	_						
	9.	937 (1997) Richard, J. and Frey,	P.A., "Stere	ochemical Course of T J. Am. Chem. Soc., 10	「hiopho <u>0</u> :7757-	 sphor 7758 (yl Group 1978)	Transf	er	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

PTO FORM 1449

ATTORNEY DOCKET NO. 03678.0064.CPUS02	APPLICATION NO. 10/814,007						
APPLICANT							
BOYER, et al.							
FILING DATE	GROUP						
March 30, 2004	Not yet Assigned						

,	12.	Zatorski, A. et al., "Chemical Synthesis of Benzamide Adenine Dinucleotide: Inhibition of Inosine Monophosphate Dehydrogenase (Types I and II)", Journal of Medicinal Chemistry, American Chemical Society, 39:2422-2426 (1996)					
EXAMINER	!		DATE CONSIDERED				